Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 31NIH 16INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Dermatologic 1

Conditions

Melanoma 1Advanced Solid Tumors 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × CTLA-4 Antigen × Clear all
NCT03545971 2023-02-28

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
53 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT00050102 2011-01-28

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma

Bristol-Myers Squibb

Phase 2 Completed
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡